Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding…
Continue Reading-
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Stockholm, Sweden, 12 July 2022 – Gesynta Pharma AB today announces that all patients have…
Continue Reading -
Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension
Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted…
Continue Reading -
Vi søker jurist!
Om stillingen Vi har behov for å styrke vår interne juridiske kompetanse. Som advokat/jurist i…
Continue Reading -
Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension
Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro...
Continue Reading -
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG…
Continue Reading -
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for…
Continue Reading -
Alex Therapeutics raises €3.5M in oversubscribed financing round
Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies…
Continue Reading -
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
Continue Reading -
Ribbon Biolabs raises EUR 18 million in its Series A financing
Ribbon Biolabs Raises EUR 18 Million Series A Financing
Continue Reading